Takeda Ventures

Corporate VC Active San Diego, United States Est. 2001
Visit website ↗ LinkedIn
Last updated 2026-06-18
Portfolio
7
in our dataset
Rounds participated
9
Rounds led
0
Rounds' value
$147.9M
total disclosed, rounds participated
Stages
Seed, A Round, B Round

About

Takeda Ventures (TVI) is the corporate investment arm of Takeda Pharmaceuticals. It invests in current and future areas of interest for Takeda Pharmaceuticals. As a strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts through clinical proof of concept. Takeda Ventures also strives to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Takeda Ventures focuses on high-caliber therapeutic and platform based opportunities around the world. It invests in early-stage opportunities that complement Takedas pipeline and products. TVI's mission is to create strategic growth opportunities for Takeda by investing and nurturing Innovative Life Science Companies in areas aligned with Takedas R&D focuses which include; Oncology, Gastroenterology, Neuroscience, and Rare Disease. TVI's aim is to access and support therapeutic and platform innovation working closely with academic innovator, entrepreneurs and investors. It invest in seeds or syndicated venture investing providing to the companies access to the resources of a multinational pharmaceutical company.

Portfolio · 7

ImmPACT Bio
CAR-T Cell Therapies for Treating Cancer
1 round $18.0M committed Latest: 2020-08
Emendo Biotherapeutics
DNA Correction and Genome-editing Platforms
1 round $61.0M committed Latest: 2020-01
BiomX
Microbiome Therapies for Chronic Diseases
2 rounds $56.0M committed Latest: 2019-02
Bsense Bio Therapeutics
Neuropathic Pain Treatment
1 round $2.7M committed Latest: 2018-09
Ramino-Bio
Oral drug for treating cardio-metabolic disease and rare MSUD
1 round Latest: 2018-09
Protekt Therapeutics
PKR Inhibition for Treating Neurodegenerative Diseases
2 rounds $10.3M committed Latest: 2017-05
Pi Therapeutics
Inhibitors for Cancer Treatment
1 round Latest: 2017-01

Investment activity

2 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences7

Q&A

What is Takeda Ventures' primary investment focus?
Takeda Ventures, the corporate investment arm of Takeda Pharmaceuticals, focuses on high-caliber therapeutic and platform-based opportunities globally, particularly in areas aligned with Takeda's R&D focuses, including Oncology, Gastroenterology, Neuroscience, and Rare Disease.
What are some of Takeda Ventures' notable exits?
Takeda Ventures has seen exits including ImmPACT Bio, which was acquired by Lyell Immunopharma in October 2024, and BiomX, which completed a reverse merger in November 2019.
Which investment stages does Takeda Ventures typically target?
Takeda Ventures invests in Seed, A Round, and B Round stages, with a focus on early-stage opportunities.
Can you name some of Takeda Ventures' portfolio companies?
Takeda Ventures' portfolio includes companies such as BiomX, focused on microbiome therapies, and ImmPACT Bio, which develops CAR-T cell therapies for cancer.
What is Takeda Ventures' geographic focus for investments?
Takeda Ventures focuses on therapeutic and platform-based opportunities around the world, without specific preferred geographies listed beyond a global scope.
When was Takeda Ventures founded?
Takeda Ventures was founded in 2001.
What is the most recent exit for Takeda Ventures?
The most recent exit for Takeda Ventures was ImmPACT Bio, which was acquired by Lyell Immunopharma in October 2024.
What is the sector concentration of Takeda Ventures' investments?
Takeda Ventures shows a strong concentration in the Health Tech & Life Sciences sector, with all 7 of its portfolio companies and 9 investment rounds falling within this sector.
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)